Product Description
HysensBio is developing KH-001 as a treatment for dentin sensitivity. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04804514)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral, Vaginal
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Byoung-Moo Seo
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Korea, United States
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Dentin Sensitivity|Premature Ejaculation
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07434271 |
KH-001-02 | P2 |
Recruiting |
Premature Ejaculation |
2026-05-03 |
12% |
2026-02-26 |
Primary Endpoints|Treatments |
NCT06464939 |
KH-001-G201 | P2 |
Completed |
Dentin Sensitivity |
2025-12-22 |
12% |
2026-01-14 |
Primary Endpoints|Treatments|Trial Status |
NCT06264453 |
KH-001-D201 | P2 |
Completed |
Dentin Sensitivity |
2024-09-25 |
12% |
2025-03-18 |
|
NCT04804514 |
KH001sol-01 | P2 |
Completed |
Dentin Sensitivity |
2023-03-03 |
12% |
2025-02-28 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |